Twist Bioscience Co. (NASDAQ:TWST) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Twist Bioscience Co. (NASDAQ:TWST) have been assigned an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $51.22.

TWST has been the subject of several analyst reports. Barclays cut their target price on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. The Goldman Sachs Group lifted their price objective on Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, July 9th. Robert W. Baird lifted their price objective on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research report on Monday, August 5th. Evercore ISI lifted their price objective on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Finally, JPMorgan Chase & Co. lifted their price objective on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research report on Monday, August 5th.

Insider Transactions at Twist Bioscience

In other news, CFO Adam Laponis sold 856 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $41.81, for a total transaction of $35,789.36. Following the completion of the sale, the chief financial officer now owns 73,397 shares in the company, valued at $3,068,728.57. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, CFO Adam Laponis sold 856 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $41.81, for a total transaction of $35,789.36. Following the completion of the sale, the chief financial officer now owns 73,397 shares in the company, valued at $3,068,728.57. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Dennis Cho sold 709 shares of Twist Bioscience stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $39.93, for a total transaction of $28,310.37. Following the sale, the insider now owns 78,996 shares of the company’s stock, valued at approximately $3,154,310.28. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 42,300 shares of company stock worth $1,801,822 in the last quarter. 3.92% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Signaturefd LLC boosted its stake in Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after acquiring an additional 306 shares during the last quarter. EdgeRock Capital LLC bought a new position in Twist Bioscience during the 2nd quarter worth approximately $43,000. Blue Trust Inc. boosted its stake in Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after acquiring an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new position in Twist Bioscience during the 2nd quarter worth approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after acquiring an additional 381 shares during the last quarter.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $40.36 on Friday. The company has a market capitalization of $2.35 billion, a PE ratio of -12.24 and a beta of 1.77. Twist Bioscience has a one year low of $15.11 and a one year high of $60.90. The business has a 50 day simple moving average of $43.77 and a 200 day simple moving average of $44.94.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.71). The company had revenue of $81.50 million for the quarter, compared to the consensus estimate of $77.40 million. Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. Twist Bioscience’s quarterly revenue was up 27.7% compared to the same quarter last year. During the same quarter last year, the business earned ($1.01) EPS. Equities analysts anticipate that Twist Bioscience will post -3.13 earnings per share for the current fiscal year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.